New Biomarkers Predict CKD Progression More Accurately Than Creatinine Alone

Expanded Summary

This longitudinal study followed over 2,500 CKD patients for up to 5 years and measured new biomarkers in addition to standard labs.

Key Findings

Biomarkers tested:

TNFR-1, TNFR-2, and KIM-1 (inflammatory and tubular injury markers).

Predictive power:

These markers identified patients at high risk of rapid progression—even when eGFR appeared stable.

Modeling improvement:

Algorithms combining biomarkers + eGFR were 30–40% more accurate than eGFR alone.

Implications

In the near future, blood tests for these biomarkers could help nephrologists stratify risk and personalize treatment. Early warning could mean earlier intervention—and better outcomes.